Roberto Ria
Has grant
Professore Ordinario
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Roberto Ria is a Professore Ordinario at the Università Degli Studi di Bari Aldo Moro, in the Dipartimento di Scienze Biomediche ed Oncologia Umana, Italy. His research areas include immunology and oncology, with a particular focus on multiple myeloma, lung conditions, and ocular manifestations related to various hematological disorders. Recent publications examine the interplay of immune dysfunction in cancer and the implications of therapeutic interventions on patient health outcomes.
Recent Grants
Grant: Close
NUOVI FARMACI NEL TRATTAMENTO DEL MIELOMA MULTIPLO VALUTAZIONE DEL LORO EFFETTO A LIVELLO DEL MICROAMBIENTE OSSEO E IDENTIFICAZIONE DI MARCATORI PROGNOSTICI MOLECOLARI
Open Date: 2009-01-01
Close Date: 2011-01-01
Articles (15)
Year:
2025
Year:
2025
Introduction: Lung ultrasound (LUS) is widely used in clinical practice for identifying interstitial lung diseases (ILDs) and assessing their progression. Although high-resolution computed tomography (HRCT) remains the gold standard for evaluating the severity of ILDs, LUS can be performed as a screening method or as a follow-up tool post-HRCT. Minimum training is needed to better identify typical lesions, and the integration of innovative artificial intelligence (AI) automatic algorithms may enhance diagnostic efficiency. Aim: This study aims to assess the effectiveness of a novel AI algorithm in automatic ILD recognition and scoring in comparison to an expert LUS sonographer. The “SensUS Lung” device, equipped with an automatic algorithm, was employed for the automatic recognition of the typical ILD patterns and to calculate an index grading of the interstitial involvement. Methods: We selected 33 Caucasian patients in follow-up for ILDs exhibiting typical HRCT patterns (honeycombing, ground glass, fibrosis). An expert physician evaluated all patients with LUS on twelve segments (six per side). Next, blinded to the previous evaluation, an untrained operator, a non-expert in LUS, performed the exam with the SensUS device equipped with the automatic algorithm (“SensUS Lung”) using the same protocol. Pulmonary functional tests (PFT) and DLCO were conducted for all patients, categorizing them as having reduced or preserved DLCO. The SensUS device indicated different grades of interstitial involvement named Lung Staging that were scored from 0 (absent) to 4 (peak), which was compared to the Lung Ultrasound Score (LUS score) by dividing it by the number of segments evaluated. Statistical analyses were done with Wilcoxon tests for paired values or Mann–Whitney for unpaired samples, and correlations were performed using Spearman analysis; p < 0.05 was considered significant. Results: Lung Staging was non-inferior to LUS score in identifying the risk of ILDs (median SensUS 1 [0–2] vs. LUS 0.67 [0.25–1.54]; p = 0.84). Furthermore, the grade of interstitial pulmonary involvement detected with the SensUS device is directly related to the LUS score (r = 0.607, p = 0.002). Lung Staging values were inversely correlated with forced expiratory volume at first second (FEV1%, r = −0.40, p = 0.027), forced vital capacity (FVC%, r = −0.39, p = 0.03) and forced expiratory flow (FEF) at 25th percentile (FEF25%, r = −0.39, p = 0.02) while results directly correlated with FEF25–75% (r = 0.45, p = 0.04) and FEF75% (r = 0.43, p = 0.01). Finally, in patients with reduced DLCO, the Lung Staging was significantly higher, overlapping the LUS (reduced median 1 [1–2] vs. preserved 0 [0–1], p = 0.001), and overlapping the LUS (reduced median 18 [4–20] vs. preserved 5.5 [2–9], p = 0.035). Conclusions: Our data suggest that the considered AI automatic algorithm may assist non-expert physicians in LUS, resulting in non-inferior-to-expert LUS despite a tendency to overestimate ILD lesions. Therefore, the AI algorithm has the potential to support physicians, particularly non-expert LUS sonographers, in daily clinical practice to monitor patients with ILDs. The adopted device is user-friendly, offering a fully automatic real-time analysis. However, it needs proper training in basic skills.
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Collaborators (11)
Angelo Vacca
-
Giacomo Boscia
University of Turin
Gianfranco LAULETTA
University of Bari Aldo Moro
Vanessa Desantis
-
Davide Fiore Bavaro
University of Bari
Marialuisa Sveva Marozzi
University of Bari Aldo Moro
Leonardo A. Sechi
University of Udine
ANTONIO GIOVANNI SOLIMANDO
University of Bari Aldo Moro
Jean-Francois Desaphy
Associate Professor of Pharmacology
University of Bari Aldo Moro
Mario Testini
University of Bari Aldo Moro
monica montagnani
Professore Associato
Università degli Studi di Bari Aldo Moro Scuola di Medicina
Make your next move.
Prepare your application
Review drafts before you send them.